John G Ullman & Associates Inc. Grows Position in Thermo Fisher Scientific Inc. $TMO

John G Ullman & Associates Inc. increased its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 29.9% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 11,614 shares of the medical research company’s stock after acquiring an additional 2,671 shares during the quarter. John G Ullman & Associates Inc.’s holdings in Thermo Fisher Scientific were worth $4,709,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. CBIZ Investment Advisory Services LLC lifted its position in shares of Thermo Fisher Scientific by 137.5% during the first quarter. CBIZ Investment Advisory Services LLC now owns 57 shares of the medical research company’s stock valued at $28,000 after buying an additional 33 shares during the last quarter. Anderson Financial Strategies LLC purchased a new stake in shares of Thermo Fisher Scientific during the first quarter valued at about $30,000. Keystone Global Partners LLC purchased a new stake in shares of Thermo Fisher Scientific during the first quarter valued at about $31,000. IMA Advisory Services Inc. purchased a new stake in shares of Thermo Fisher Scientific during the first quarter valued at about $35,000. Finally, Smallwood Wealth Investment Management LLC acquired a new position in shares of Thermo Fisher Scientific during the first quarter valued at about $37,000. 89.23% of the stock is owned by hedge funds and other institutional investors.

Thermo Fisher Scientific Price Performance

Shares of NYSE TMO opened at $539.05 on Friday. Thermo Fisher Scientific Inc. has a 12 month low of $385.46 and a 12 month high of $610.97. The stock has a market capitalization of $203.55 billion, a price-to-earnings ratio of 31.18, a PEG ratio of 2.93 and a beta of 0.77. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.93 and a quick ratio of 1.50. The firm’s 50 day simple moving average is $495.74 and its 200-day simple moving average is $449.13.

Thermo Fisher Scientific (NYSE:TMO) last announced its earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.22 by $0.14. The firm had revenue of $10.86 billion for the quarter, compared to analyst estimates of $10.68 billion. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The business’s revenue was up 2.9% on a year-over-year basis. During the same quarter last year, the firm posted $5.37 EPS. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. Analysts expect that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Analyst Ratings Changes

TMO has been the topic of several recent analyst reports. Royal Bank Of Canada set a $561.00 price objective on shares of Thermo Fisher Scientific and gave the company an “outperform” rating in a report on Tuesday, September 2nd. HSBC restated a “hold” rating and set a $510.00 price objective on shares of Thermo Fisher Scientific in a report on Thursday, July 24th. UBS Group upped their price objective on shares of Thermo Fisher Scientific from $460.00 to $500.00 and gave the company a “neutral” rating in a report on Thursday, July 24th. Robert W. Baird upped their price objective on shares of Thermo Fisher Scientific from $553.00 to $567.00 and gave the company an “outperform” rating in a report on Thursday, July 24th. Finally, Evercore ISI upped their price objective on shares of Thermo Fisher Scientific from $525.00 to $590.00 and gave the company an “outperform” rating in a report on Tuesday, October 7th. Fifteen investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $589.10.

Insider Transactions at Thermo Fisher Scientific

In other news, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $500.96, for a total transaction of $5,009,600.00. Following the transaction, the chief executive officer owned 115,174 shares in the company, valued at $57,697,567.04. The trade was a 7.99% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Gianluca Pettiti sold 400 shares of Thermo Fisher Scientific stock in a transaction on Friday, July 25th. The stock was sold at an average price of $479.98, for a total value of $191,992.00. Following the transaction, the executive vice president owned 22,367 shares in the company, valued at approximately $10,735,712.66. This represents a 1.76% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 30,066 shares of company stock worth $14,182,963 in the last quarter. Company insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.